Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jerry S Wolinsky

Showing results (71-80 of 139) with videos related to

Pageof 14
Sort By:
Annals of Neurology|February 21, 2013
Randomized study combining interferon and glatiramer acetate in multiple sclerosisFred D Lublin, Stacey S Cofield, Gary R Cutter, et al.
Journal of Magnetic Resonance Imaging : JMRI|November 26, 2013
Contrast enhanced MR venography with gadofosveset trisodium: evaluation of the intracranial and extracranial venous systemLarry A Kramer, Alan M Cohen, Khader M Hasan, et al.
Neurology|September 3, 2021
Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple SclerosisStephen L Hauser, Ludwig Kappos, Xavier Montalban, et al.
JAMA Neurology|June 9, 2020
Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical TrialsLudwig Kappos, Jerry S Wolinsky, Gavin Giovannoni, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 12, 2021
Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trialBianca Weinstock-Guttman, Robert Bermel, Gary Cutter, et al.
The New England Journal of Medicine|October 14, 2011
Randomized trial of oral teriflunomide for relapsing multiple sclerosisPaul O'Connor, Jerry S Wolinsky, Christian Confavreux, et al.
Annals of Clinical and Translational Neurology|February 17, 2025
Ethnoracial disparities in gray matter atrophy are mediated by structural disconnectivity in multiple sclerosisAhmed Bayoumi, Joseph A Thomas, Breanna R Alonzo, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 18, 2017
The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studiesMark S Freedman, Jerry S Wolinsky, Giancarlo Comi, et al.
Annals of Neurology|August 30, 2018
Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trialJerry S Wolinsky, Xavier Montalban, Stephen L Hauser, et al.
Neuroimage. Clinical|November 2, 2013
Regional cortical thickness in relapsing remitting multiple sclerosis: A multi-center studyPonnada A Narayana, Koushik A Govindarajan, Priya Goel, et al.
Pageof 14

Showing results (71-80 of 139) with videos related to

Sort By:
Pageof 14
Annals of Neurology|February 21, 2013
Randomized study combining interferon and glatiramer acetate in multiple sclerosisFred D Lublin, Stacey S Cofield, Gary R Cutter, et al.
Journal of Magnetic Resonance Imaging : JMRI|November 26, 2013
Contrast enhanced MR venography with gadofosveset trisodium: evaluation of the intracranial and extracranial venous systemLarry A Kramer, Alan M Cohen, Khader M Hasan, et al.
Neurology|September 3, 2021
Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple SclerosisStephen L Hauser, Ludwig Kappos, Xavier Montalban, et al.
JAMA Neurology|June 9, 2020
Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical TrialsLudwig Kappos, Jerry S Wolinsky, Gavin Giovannoni, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 12, 2021
Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trialBianca Weinstock-Guttman, Robert Bermel, Gary Cutter, et al.
The New England Journal of Medicine|October 14, 2011
Randomized trial of oral teriflunomide for relapsing multiple sclerosisPaul O'Connor, Jerry S Wolinsky, Christian Confavreux, et al.
Annals of Clinical and Translational Neurology|February 17, 2025
Ethnoracial disparities in gray matter atrophy are mediated by structural disconnectivity in multiple sclerosisAhmed Bayoumi, Joseph A Thomas, Breanna R Alonzo, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 18, 2017
The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studiesMark S Freedman, Jerry S Wolinsky, Giancarlo Comi, et al.
Annals of Neurology|August 30, 2018
Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trialJerry S Wolinsky, Xavier Montalban, Stephen L Hauser, et al.
Neuroimage. Clinical|November 2, 2013
Regional cortical thickness in relapsing remitting multiple sclerosis: A multi-center studyPonnada A Narayana, Koushik A Govindarajan, Priya Goel, et al.
Pageof 14